Blog

Aug 27, 2023

FDA removes neurologist with financial ties from Alzheimer's panel

By Ed Silverman June 5, 2023 The Food and Drug Administration has removed a

By Ed Silverman June 5, 2023

The Food and Drug Administration has removed a neurologist with financial ties to Biogen and Eisai — which jointly develop and market a pair of controversial Alzheimer's drugs — from an upcoming advisory panel meeting to review one of those treatments.

David Weisman was cleared two months ago by the agency as a temporary voting member of an advisory committee that will meet Friday to consider whether a drug called lecanemab, which is promoted by the companies, should be fully approved by the FDA. The drug was given an accelerated approval earlier this year based on evidence suggesting it can help people with mild cognitive decline.

advertisement

However, the drug is being closely watched due to uncertainty over the extent of its effectiveness, concerns over side effects, controversy over the FDA approval process for an earlier Alzheimer's drug from the same companies, and debate over Medicare coverage. And the stakes are high, given the clamor for Alzheimer's treatments that can make even a small difference in patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Alzheimer's

biotech

FDA

neurology

pharmaceuticals

STAT+

This name will appear with your comment

There was an error saving your display name. Please check and try again.